A Phase I Study of CFT8919 in Patients With Advanced NSCLC

NCT06641609 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer With EGFR Mutation

Interventions

DRUG: Dose-Escalation (Phase Ia) CFT8919 capsule
DRUG: Dose-Expansion (Phase Ib) CFT8919 capsule
DRUG: Cohort-Expansion (Phase Ic) CFT8919 capsule

Sponsor

Betta Pharmaceuticals Co., Ltd.